Table 1.
EoE Clinical Characteristics
| Clinical Characteristics | Number of Patients (%) N=257 |
|---|---|
| Symptoms | |
| Dysphagia | 209 (81%) |
| Food Impaction | 148 (58%) |
| GERD | 212 (82%) |
| Nausea/Vomiting | 22 (9%) |
| Abdominal Pain | 12 (5%) |
| Regurgitation | 16 (6%) |
| Chest Pain | 17 (7%) |
| Choking | 18 (7%) |
| Other | 19 (7%) |
| Duration of Symptoms | |
| <1 year | 29 (11%) |
| 1–5 years | 72 (28%) |
| 5–10 years | 30 (12%) |
| >10 years | 75 (29%) |
| Unknown | 50 (49%) |
| Severity | |
| ED Visit | 71 (28%) |
| Procedure-FI | 46 (18%) |
| Dilation | 100 (39%) |
| Peripheral Eosinophils | |
| >500 | 43 (17%) |
| <500 | 137 (53%) |
| Unknown | 77 (30%) |
| Endoscopic Findings | |
| Rings | 143 (56%) |
| Furrows | 89 (35%) |
| Strictures | 102 (40%) |
| Treatment Recommendation | |
| PPI | 179 (70%) |
| H2 Blocker | 27 (10%) |
| Swallowed Steroid | 189 (74%) |
| Oral Prednisone/Entocort | 12 (5%) |
| Montelukast | 11 (4%) |
| None | 4 (2%) |
| Food Avoidance Total (with or without other treatments | 103 (40%) |
| Food Avoidance Only | 10 (4%) |
| Food Avoidance + PPI Only | 32 (12%) |
| PPI and Swallowed Steroid | 133 (52%) |
| Any Combination of >1 Medicine | 150 (58%) |
| Reported Outcomes | |
| Partial Improvement | 39 (15%) |
| Complete Improvement | 118 (46%) |
| Worse | 4 (2%) |
| No Change | 23 (9%) |
| Unknown | 73 (28%) |